We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Physical Activity and Thrombophilic Risk Investigated

By LabMedica International staff writers
Posted on 18 Feb 2020
Among the effects of physical exercise on coagulation, the influence on protein anticoagulant system and PC deficiency-related thrombophilic risk are still controversial. More...
The impact of physical activity on the coagulation system has been described.

Physical activity (PA) determines a shortening of the activated partial thromboplastin time (APTT) and an increase of the factor VIII. On the other hand, little is known about the variations of the anticoagulant determinants and specifically of Protein C (PC) system, during PA, and in the subsequent recovery phase.

Hematologists at the Ospedale Fatebenefratelli (Naples, Italy) and their colleagues analyzed the variations of the PC system in healthy subjects (12 males, age 18–43 years; mean: 28.5 ± 5.30) performing a treadmill procedure. They measured the APTT before and after activation of endogenous PC, in these subjects before and after a physical exercise and during the subsequent recovery phase (up to one hour). Protein C activity-dependent clotting time (PCAT) was measured on all blood samples by ProC Global test (Siemens Healthcare, Malvern, PA, USA). APTT was also assayed using Siemens Healthcare Pathromtin SL, with a BCS instrument.

The team reported that for the 20 participants in the study, APTT values decreased slightly, i.e., from a basal value of 37.5 seconds (35.0–42.0) to 34.0 seconds (31.0–39.3) and to 35.5 seconds (32.3–38.0) at 15 and at 30 minutes post-exercise respectively. On the other hand, the Pro C values progressively dropped from a median basal level of 123 seconds (114.7–152.3) to 84.5 seconds (78.3–91.0) at 30 minutes post-exercise and returned to baseline levels at 60 minutes.

The authors concluded that the their study shows that the coagulation unbalance observed after strenuous exercise and with no consequence in healthy individuals with normal PC level, could increase the thrombophilic risk in silent carriers of significant defects of the protein C system and occasionally trigger an episode of deep vein thrombosis. The study was published on January 30, 2020 in the Journal of Blood Medicine.

Related Links:
Ospedale Fatebenefratelli
Siemens Healthcare



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.